A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients

Running, not enrolling · Phase 2 · Has a placebo group

Conditions studied: Hypertension

In brief

The purpose of this study is to evaluate the efficacy, safety and tolerability of QCZ484 or placebo, given subcutaneously, every 6 months, at different dose levels in patients with mild to moderate hypertension

Key facts

Study ID

NCT06857955

Run by

Novartis Pharmaceuticals

People needed

399

Starts

2025-03-26

Expected to finish

2028-04-05

Last updated by the study team

2026-07-06

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Signed informed consent.
• Males or females aged 18 to 75 years.
• Diagnosis of hypertension.
• Hypertension treatment naive or on maximum 2 anti-HTN medications and able to undergo washout for 4 weeks.
• Mean sitting SBP ≥140 mmHg measured by OBPM and mean 24 hr SBP ≥130 mmHg and <160 mmHg measured by ABPM.
• Participants able to understand and comply with study procedures.

You may not qualify if…

• Known history of secondary hypertension.
• Orthostatic hypotension.
• Laboratory parameter assessments outside of range at screening.
• Evidence of hepatic disease.
• Medical condition, other than hypertension, requiring treatment with RAAS inhibitor.
• Any history of congestive heart failure.
• Current or history of intolerance to ACEi and/or ARBs.
• Clinically significant cardiac arrhythmias, high-grade AV block and third-degree AV block within 6 months prior to screening.
• Acute myocardial infarction (AMI) or unstable angina, or any percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) within 12 months prior to screening. Any history of ischemic or hemorrhagic stroke or transient ischemic attack any time prior to screening.
• Other protocol-defined inclusion/exclusion criteria may apply

Where it is running

• UAB St Vincents — Birmingham, Alabama, United States
• Longwood Research — Huntsville, Alabama, United States
• The Center for Clinical Trials — Saraland, Alabama, United States
• Elite Clinical Studies — Phoenix, Arizona, United States
• Synexus Clinical Research US Inc — Tucson, Arizona, United States
• NICRs Research Center — Garden Grove, California, United States
• Valiance Clinical Research — Huntington Park, California, United States
• Downtown L A Research Center Inc — Los Angeles, California, United States
• Clinical Trials Research Sacramento — Sacramento, California, United States
• Encompass Clinical Research — Spring Valley, California, United States
• Clinical Research of Brandon LLC — Brandon, Florida, United States
• ALL Medical Research LLC — Cooper City, Florida, United States
• National Research Institute — Hialeah, Florida, United States
• Cen Exel RCA — Hollywood, Florida, United States
• East Coast Institute for Research — Jacksonville, Florida, United States
• Entrust Clinical Research — Miami, Florida, United States
• Inpatient Research Clinical LLC — Miami Lakes, Florida, United States
• Suncoast Clinical Research — New Port Richey, Florida, United States
• Renstar Medical Research — Ocala, Florida, United States
• American Research Centers of FL — Pembroke Pines, Florida, United States
• Cen Exel FCR — Tampa, Florida, United States
• Cardiology Partners Clinical Research Institute — Wellington, Florida, United States
• Centricity Research — Columbus, Georgia, United States
• Javara Research — Fayetteville, Georgia, United States
• SEC Clinical Research LLC — Andalusia, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.